<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">7917939</article-id><article-id pub-id-type="pmc">2033397</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A Cancer Research Campaign (CRC) phase II trial of CB10-277 given by 24 hour infusion for malignant melanoma.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bleehen</surname><given-names>N. M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Calvert</surname><given-names>A. H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>S. M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Harper</surname><given-names>P.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kaye</surname><given-names>S. B.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Judson</surname><given-names>I.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Brampton</surname><given-names>M.</given-names></name></contrib></contrib-group><aff>University Department, Addenbrooke's Hospital, Cambridge, UK.</aff><pub-date pub-type="ppub"><month>10</month><year>1994</year></pub-date><volume>70</volume><issue>4</issue><fpage>775</fpage><lpage>777</lpage><abstract><p>The decarbazine analogue CB10-277 has been investigated for anti-tumour activity in a phase II study on malignant melanoma. Treatment was administered as a slow infusion of 12,000 mg m-2 over 24 h and repeated every 3 weeks. A total of 28 patients were entered into the study, of whom 23 were eligible for review. A total of 64 courses was given. There was one objective partial response in 22 patients assessable for response. The major toxicities were leucopenia and thrombocytopenia. CB10-277 in this schedule therefore does not appear to have major activity in melanoma.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00056-0205.tif" xlink:title="scanned-page" xlink:role="775" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00056-0206.tif" xlink:title="scanned-page" xlink:role="776" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00056-0207.tif" xlink:title="scanned-page" xlink:role="777" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

